Publication:
N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: Translational pharmacokinetics

dc.contributor.authorHanly, Lauren N. (26658375100)
dc.contributor.authorChen, Nancy (11640759900)
dc.contributor.authorAleksa, Katarina (7801495439)
dc.contributor.authorCutler, Murray (14065951200)
dc.contributor.authorBajcetic, Milica (15727461400)
dc.contributor.authorPalassery, Rasmi (54883944700)
dc.contributor.authorRegueira, Osvaldo (6508160650)
dc.contributor.authorTurner, Curtis (7402367015)
dc.contributor.authorBaw, Bandar (9332411000)
dc.contributor.authorMalkin, Becky (15723932000)
dc.contributor.authorFreeman, David (35597840200)
dc.contributor.authorRieder, Michael J. (7006328846)
dc.contributor.authorVasylyeva, Tetyana L. (8639929600)
dc.contributor.authorKoren, Gideon (36042259400)
dc.date.accessioned2025-06-12T22:26:12Z
dc.date.available2025-06-12T22:26:12Z
dc.date.issued2012
dc.description.abstractIfosfamide (IFO), which is used in the treatment of pediatric solid tumors, causes high rates of nephrotoxicity. N-acetylcysteine (NAC), an antidote for acetaminophen overdose, has been shown to prevent IFO-induced renal cell death and nephrotoxicity in both LLCPK-1 cells and a rat model. To facilitate the use of NAC in preventing IFO-induced nephrotoxicity in children, the authors compared the systemic exposure to NAC in children treated for acetaminophen overdose to the systemic exposure of the therapeutically effective rat model. The mean systemic exposure in the rat model was 18.72 mM•h (range, 9.92-30.02 mM•h), compared to the mean systemic exposure found in treated children (14.48 mM•h; range, 6.22-32.96 mM•h). They also report 2 pediatric cases in which NAC-attenuated acute renal failure associated with IFO when given concurrently with their chemotherapy treatment. Systemic exposure to NAC measured in 1 of these cases was comparable to that in the children treated for acetaminophen overdose. These results corroborate NAC's potential to protect against IFO-induced nephrotoxicity in children when used in its clinically approved dose schedule and supports a clinical trial in children. © 2012 American College of Clinical Pharmacology, Inc.
dc.identifier.urihttps://doi.org/10.1177/0091270010391790
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84855427456&doi=10.1177%2f0091270010391790&partnerID=40&md5=df5f1395e7a6d46cc58275be6f44ab72
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/9906
dc.subjectchildren
dc.subjectIfosfamide
dc.subjectN-acetylcysteine
dc.subjectnephrotoxicity
dc.subjectprevention
dc.titleN-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: Translational pharmacokinetics
dspace.entity.typePublication

Files